Using the KTP/532 laser to control epistaxis in patients with hereditary hemorrhagic telangiectasia
- PMID: 8545698
- DOI: 10.1097/00007611-199601000-00014
Using the KTP/532 laser to control epistaxis in patients with hereditary hemorrhagic telangiectasia
Abstract
Osler-Weber-Rendu disease remains a challenging clinical management problem. We have found the potassium-titanyl-phosphate laser (KTP/532) for photocoagulation of intranasal telangiectases to be useful in controlling epistaxis refractory to traditional surgical therapy. We present the case of a patient who had Osler-Weber-Rendu disease previously treated with partial septectomy, turbinectomy, and intranasal dermoplasty. A technique using the KTP laser for photocoagulation of intranasal telangiectases is described. This technique has resulted in reducing the frequency of epistaxis, decreasing the need for transfusions, diminishing hospital admissions, and improving quality of life for this patient. The KTP laser plays an important role in the management of recurrent epistaxis in patients with Osler-Weber-Rendu disease.
Similar articles
-
Comparison of electrosurgical plasma coagulation and potassium-titanyl-phosphate laser photocoagulation for treatment of hereditary hemorrhagic telangiectasia-related epistaxis.Int Forum Allergy Rhinol. 2014 Aug;4(8):640-5. doi: 10.1002/alr.21328. Epub 2014 Apr 9. Int Forum Allergy Rhinol. 2014. PMID: 24719397 Clinical Trial.
-
Surgical management of life-threatening epistaxis in Osler-Weber-Rendu disease.Ann Plast Surg. 1995 Aug;35(2):208-13. doi: 10.1097/00000637-199508000-00017. Ann Plast Surg. 1995. PMID: 7486747
-
Laser-Assisted Control of Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Systematic Review.Lasers Surg Med. 2020 Apr;52(4):293-300. doi: 10.1002/lsm.23147. Epub 2019 Aug 22. Lasers Surg Med. 2020. PMID: 31441079 Free PMC article.
-
The impact of septodermoplasty and potassium-titanyl-phosphate (KTP) laser therapy in the treatment of hereditary hemorrhagic telangiectasia-related epistaxis.Am J Rhinol. 2008 Mar-Apr;22(2):182-7. doi: 10.2500/ajr.2008.22.3145. Am J Rhinol. 2008. PMID: 18416977
-
[Treatment of recurrent epistaxis in Rendu-Osler-Weber disease].HNO. 1997 Sep;45(9):673-81. doi: 10.1007/s001060050141. HNO. 1997. PMID: 9417448 Review. German.
Cited by
-
Hereditary haemorrhagic telangiectasia treated by pulsed neodymium:yttrium-aluminium-garnet (Nd:YAG) laser (1,064 nm).Lasers Med Sci. 2008 Oct;23(4):385-91. doi: 10.1007/s10103-007-0512-4. Epub 2007 Nov 13. Lasers Med Sci. 2008. PMID: 17999126
-
Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations: issues in clinical management and review of pathogenic mechanisms.Thorax. 1999 Aug;54(8):714-29. doi: 10.1136/thx.54.8.714. Thorax. 1999. PMID: 10413726 Free PMC article. Review. No abstract available.
-
Diode laser in the treatment of epistaxis in patients with hereditary haemorrhagic telangiectasia.Acta Otorhinolaryngol Ital. 2012 Jun;32(3):164-9. Acta Otorhinolaryngol Ital. 2012. PMID: 22767981 Free PMC article.
-
Management of epistaxis in hereditary hemorrhagic telangiectasia by Nd:YAG laser and quality of life assessment using the HR-QoL questionnaire.Eur Arch Otorhinolaryngol. 2005 Oct;262(10):830-3. doi: 10.1007/s00405-004-0911-0. Epub 2005 Mar 1. Eur Arch Otorhinolaryngol. 2005. PMID: 15739086 Clinical Trial.
-
Treatment of the skin manifestations of hereditary hemorrhagic telangiectasia with pulsed dye laser.Lasers Med Sci. 2014 Jan;29(1):321-4. doi: 10.1007/s10103-013-1346-x. Epub 2013 May 17. Lasers Med Sci. 2014. PMID: 23681198
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources